A Dual Commercial Opportunity

Age-related conduction disease and bradyarrhythmias are expanding the number of patients who may require permanent cardiac pacing

More patients are living longer with rhythm disorders, cardiovascular disease, and implanted cardiac devices

Healthcare systems are increasingly adopting technologies intended to eliminate conventional leads and generator pockets

Patients may require generator replacements, lead revisions, system upgrades, and additional procedures over decades of pacing

These trends create sustained demand for pacing technologies designed to reduce chronic hardware burden, extend device longevity, and simplify long-term patient management.

The leadless pacemaker segment was estimated at approximately $982 million in 2025 and is projected to reach approximately $1.62 billion by 2033, growing at about 6.6% annually. This growth reflects increasing interest in pacing systems that avoid conventional transvenous leads and subcutaneous generator pockets

Unlike current intracardiac leadless pacemakers, EPIPACE is designed for placement on the external surface of the heart, outside the cardiac chambers and bloodstream.

Conventional right-ventricular pacing can produce electrical and mechanical dyssynchrony in susceptible patients. Clinical guidelines recognize that substantial right-ventricular pacing—generally 20% to 40% or more of ventricular beats—may induce cardiomyopathy in a subset of patients

Cardiac physiologic pacing strategies are intended to preserve or restore coordinated ventricular activation and reduce the risk of pacing-related ventricular dysfunction

This creates an important development opportunity for pacing systems designed to support left-ventricular activation and more physiologic contraction

EPIPACE is designed to eliminate conventional transvenous leads, avoid chronic intracardiac hardware, and reduce dependence on generator-pocket procedures

The platform is designed for direct epicardial placement on the left ventricle, creating a potential pathway toward ventricular-function preservation

Additional receivers may enable coordinated stimulation across selected cardiac locations rather than relying on activation from a single pacing site

Programmed stimulation from the apex toward the base is intended to support the heart’s natural torsional or spiral contraction pattern

EPIPACE combines the commercial potential of next-generation implantable pacing with a future expansion opportunity in physiologic pacing, ventricular synchrony, and selected heart-failure application